Export

You can select particular sections to be included in the output file.
EN
FR

Model List of Essential Medicines

clear Found 81 recommendations for 57 medicines and 18 therapeutic equivalents
2019
  1. Abiraterone General information
    Section
    Hormones and antihormones
    • Oral > Solid: 250 mg; 500 mg
    Indications
    Malignant neoplasms of prostate
  2. Aclidinium General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to tiotropium bromide for Chronic obstructive pulmonary disease
  3. Adalimumab General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL
    Indications
    Axial spondyloarthritis Crohn disease site Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    • Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL
    Indications
    Juvenile idiopathic arthritis
  4. Afatinib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung
  5. Alteplase General information
    Section
    Thrombolytic medicines
    • Parenteral > General injections > IV: 10 mg in vial powder for injection; 20 mg in vial powder for injection; 50 mg in vial powder for injection
    Indications
    Cerebral ischaemic stroke
  6. Amodiaquine + sulfadoxine + pyrimethamine General information
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Solid: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] dispersible tablets in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] dispersible tablets in co-package
    Indications
    Malaria
  7. Amoxicillin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
    • Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection
    • Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)
    • Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)
    Indications
    First choice
    Periapical abscess without sinus
  8. Amoxicillin + clavulanic acid General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
    • Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
    • Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)
    • Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)
    Indications
    Second choice
    Other specified prophylactic measures
    Section
    Antituberculosis medicines
    • Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
    • Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  9. Apixaban General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to dabigatran for Venous thromboembolism Therapeutic equivalent to dabigatran for Other specified atrial fibrillation
  10. Aprepitant General information
    Section
    Antiemetic medicines
    • Oral > Liquid: 125 mg powder for oral suspension (in sachet)
    • Oral > Solid: 80 mg; 125 mg; 165 mg
    Indications
    Nausea or vomiting
  11. Arsenic trioxide General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  12. Azithromycin General information
    Section
    Watch group antibiotics
    • Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid
    • Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)
    Indications
    First choice
    Typhoid fever Paratyphoid fever
  13. Bortezomib General information
    Section
    Targeted therapies
    • Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection
    Indications
    Plasma cell myeloma
  14. Carbetocin General information
    Section
    Uterotonics
    • Parenteral > General injections > IV: 100 µg per mL (heat stable)
    Indications
    Postpartum haemorrhage
  15. Carbimazole General information
    Section
    Thyroid hormones and antithyroid medicines
    Indications
    Therapeutic equivalent to methimazole for Thyrotoxicosis
  16. Carboplatin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL
    Indications
    Malignant neoplasms of cervix uteri
  17. Cefazolin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection
    Indications
    First choice
    Other specified prophylactic measures co-prescribed with metronidazole Other specified prophylactic measures
  18. Ceftazidime + avibactam General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  19. Ceftriaxone General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
    Indications
    First choice
    Typhoid fever Paratyphoid fever
  20. Cefuroxime General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection
    Indications
    Second choice
    Other specified prophylactic measures
  21. Certolizumab pegol General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis
  22. Ciprofloxacin General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 2 mg per mL (as hyclate)
    • Oral > Liquid: 250 mg per 5 mL (anhydrous)
    • Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)
    Indications
    First choice
    Typhoid fever Paratyphoid fever
  23. Colistin (injection) General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium) (equivalent to 34 mg colistin base activity)
    Indications
    Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  24. Cyclophosphamide General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
    • Oral > Solid > dosage form: 25 mg; 50 mg
    Indications
    Plasma cell myeloma
  25. Dabigatran General information
    Section
    Medicines affecting coagulation
    • Oral > Solid: 110 mg; 150 mg
    Indications
    Venous thromboembolism Other specified atrial fibrillation
  26. Dengue vaccine General information
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  27. Dexamethasone General information
    Section
    Hormones and antihormones
    • Oral > Solid: 4 mg
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt)
    Indications
    Plasma cell myeloma
  28. Diazoxide General information
    Section
    Medicines for hypoglycaemia
    • Oral > Liquid: 50 mg per mL
    • Oral > Solid: 50 mg
    Indications
    Persistent hyperinsulinaemic hypoglycaemia of infancy
  29. Dolutegravir + lamivudine + tenofovir General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  30. Doxorubicin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
    Indications
    Plasma cell myeloma
  31. Edoxaban General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to dabigatran for Venous thromboembolism Therapeutic equivalent to dabigatran for Other specified atrial fibrillation
  32. Enzalutamide General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to abiraterone for Malignant neoplasms of prostate
  33. Erlotinib General information
    Section
    Targeted therapies
    • Oral > Solid: 100 mg; 150 mg
    Indications
    Other specified malignant neoplasms of bronchus or lung
  34. Etanercept General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis
  35. Fexinidazole General information
    Section
    Medicines for the treatment of 1st stage African trypanosomiasis
    • Oral > Solid: 600 mg
    Indications
    African trypanosomiasis
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Oral > Solid: 600 mg
    Indications
    African trypanosomiasis
  36. Fosfomycin (injection) General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection
    Indications
    Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  37. Gefitinib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung
  38. Gentamicin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)
    Indications
    Second choice
    Other specified prophylactic measures
  39. Glecaprevir + pibrentasvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 50 mg + 20 mg granules
    • Oral > Solid > tablet: 100 mg + 40 mg
    Indications
    Chronic hepatitis C
  40. Glycopyrronium General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to tiotropium bromide for Chronic obstructive pulmonary disease
  41. Golimumab General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis
  42. Imipenem + cilastatin General information
    Section
    Antituberculosis medicines
    Indications
    Therapeutic equivalent to meropenem for Multi-drug resistant Mycobacterium tuberculosis
  43. Infliximab General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis
  44. Ivermectin General information
    Section
    Medicines for ectoparasitic infections
    • Oral > Solid > tablet: 3 mg
    Indications
    Scabies
  45. Lenalidomide General information
    Section
    Immunomodulators
    • Oral > Solid: 25 mg
    Indications
    Plasma cell myeloma
  46. Linezolid General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 mg per mL in 300 mL bag
    • Oral > Liquid: 100 mg per 5 mL powder for oral liquid
    • Oral > Solid > dispersible tablet: 150 mg
    • Oral > Solid > tablet: 600 mg
    Indications
    Methicillin resistant Staphylococcus aureus Vancomycin resistant Staphylococcus aureus Vancomycin resistant Enterococcus
  47. Lisinopril + amlodipine General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg
    Indications
    Essential hypertension
  48. Lisinopril + hydrochlorothiazide General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg
    Indications
    Essential hypertension
  49. Melphalan General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection
    • Oral > Solid: 2 mg
    Indications
    Plasma cell myeloma
  50. Meropenem General information
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  51. Meropenem + vaborbactam General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales Carbapenem resistant Acinetobacter baumannii
  52. Methimazole General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 5 mg; 10 mg; 20 mg
    Indications
    Thyrotoxicosis
  53. Metronidazole General information
    Section
    Access group antibiotics
    • Oral > Liquid: 200 mg per 5 mL (as benzoate)
    • Local > Rectal > Suppository: 500 mg; 1 g
    • Parenteral > General injections > unspecified: 500 mg per 100 mL in vial
    • Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg
    Indications
    First choice
    co-prescribed with cefazolin Other specified prophylactic measures
  54. Multiple micronutrient powder General information
    Section
    Vitamins and minerals
    • Sachets containing:
    • - iron (elemental) 12.5 mg (as coated ferrous fumarate)
    • - zinc (elemental) 5 mg
    • - vitamin A 300 micrograms
    • - with or without other micronutrients at recommended daily values
    Indications
    Iron deficiency anaemia
  55. Nivolumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion
    Indications
    Melanoma of skin
  56. Oral rehydration salts - zinc sulfate General information
    Section
    Medicines used in diarrhoea
    • Oral > Other: ORS powder for dilution and zinc sulfate solid oral dosage form 20 mg (co-packaged)
    Indications
    Diarrhoea
  57. Paclitaxel General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 6 mg per mL
    Indications
    Malignant neoplasms of cervix uteri
  58. Pegaspargase General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection
    Indications
    Lymphoid leukaemia, not elsewhere classified
  59. Pembrolizumab General information
    Section
    Immunomodulators
    Indications
    Therapeutic equivalent to nivolumab for Melanoma of skin
  60. Phenoxymethylpenicillin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
    • Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)
    Indications
    First choice
    Periapical abscess without sinus
  61. Plazomicin General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 500 mg per 10 mL
    Indications
    Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  62. Polymyxin B (injection) General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)
    Indications
    Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  63. Prednisolone General information
    Section
    Hormones and antihormones
    • Oral > Solid: 5 mg; 25 mg
    Indications
    Plasma cell myeloma Malignant neoplasms of prostate
  64. Prednisone General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to prednisolone for Plasma cell myeloma Therapeutic equivalent to prednisolone for Malignant neoplasms of prostate
  65. Procarbazine General information
    Section
    Cytotoxic medicines
    • Oral > Solid > capsule: 50 mg (as hydrochloride)
    Indications
    Hodgkin lymphoma
  66. Realgar-indigo naturalis formulation General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  67. Rivaroxaban General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to dabigatran for Venous thromboembolism Therapeutic equivalent to dabigatran for Other specified atrial fibrillation
  68. Sulfadoxine + pyrimethamine General information
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Solid: 500 mg + 25 mg tablet
    • Oral > Solid: 250 mg + 12.5 mg tablet
    Indications
    Malaria due to Plasmodium falciparum Malaria
  69. Tedizolid General information
    Section
    Reserve group antibiotics
    Indications
    Therapeutic equivalent to linezolid for Methicillin resistant Staphylococcus aureus Therapeutic equivalent to linezolid for Vancomycin resistant Staphylococcus aureus Therapeutic equivalent to linezolid for Vancomycin resistant Enterococcus
  70. Telmisartan + amlodipine General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 40 mg + 5 mg; 80 mg + 5 mg; 80 mg + 10 mg
    Indications
    Essential hypertension
  71. Telmisartan + hydrochlorothiazide General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 40 mg + 12.5 mg; 80 mg + 12.5 mg; 80 mg + 25 mg
    Indications
    Essential hypertension
  72. Thalidomide General information
    Section
    Immunomodulators
    • Oral > Solid: 50 mg
    Indications
    Plasma cell myeloma
  73. Tiotropium bromide General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > dry powder: 18 µg capsule
    • Respiratory > Inhalation > solution: 1.25 µg per actuation; 2.5 µg per actuation
    Indications
    Chronic obstructive pulmonary disease
  74. Tranexamic acid General information
    Section
    Other medicines administered to the mother
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
    Indications
    Postpartum haemorrhage
  75. Umeclidinium General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to tiotropium bromide for Chronic obstructive pulmonary disease